Immune profiling
Prioritize peptide candidates using HLA context, sequence variation and available molecular evidence.
Analyses are tailored to your experimental design, data quality and research question. The workflow and deliverables are agreed following project review.
Analysis modules
HLA genotype assessment or computational typing from suitable data.
MHC class I and class II peptide-binding analysis with appropriate predictors.
Antigen-presentation and processing predictions where supported.
Mutant and corresponding reference peptide generation.
Candidate neoantigens from SNVs and indels.
Fusion- or splice-associated peptide candidates when the data permit.
Expression, sequencing support and peptide novelty filters.
Candidate ranking with separate evidence for binding, presentation and immunogenicity.
HLA coverage and exploratory B-cell epitope analyses as project-specific extensions.
Data and metadata
Peptide lists or FASTA; supplied HLA genotype; annotated somatic VCF; expression and variant support where available. HLA inference requires suitable sequencing data, not a peptide list alone.
Proposed deliverables
Peptide–HLA result tables; evidence-annotated candidate shortlist; coverage summaries; methods and limitations.
Interpretation and feasibility
Binding, presentation and T-cell immunogenicity are distinct endpoints. Candidate prioritization does not demonstrate an immune response or clinical efficacy. B-cell epitope prediction is exploratory.
Methods and references
Methods, reference resources and software are selected for each project after protocol, feasibility and licence review. Applicable versions, references and interpretation limits are documented in the agreed workflow.